To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?

Journal of Controlled Release

Volumn 244, Issue , 2016, Pages 108-121

  Danhier, F ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Cancer; Drug delivery; EPR effect; Nanomedicine; Tumor targeting

Indexed keywords

CONTROLLED DRUG DELIVERY; DISEASES; DRUG DELIVERY; MAMMALS; TARGETED DRUG DELIVERY; TUMORS;

CANCER; CHEMOTHERAPEUTIC AGENTS; DESIGN AND DEVELOPMENT; ENHANCED PERMEABILITY AND RETENTION EFFECTS; EPR EFFECT; RESEARCH PAPERS; TUMOR MICROENVIRONMENT; TUMOR TARGETING;

MEDICAL NANOTECHNOLOGY;

BASEMENT MEMBRANE; CANCER THERAPY; ENHANCED PERMEABILITY AND RETENTION; FENESTRATION; HUMAN; NANOMEDICINE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; CHEMISTRY; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG EFFECT; EXTRACELLULAR MATRIX; METABOLISM; NEOPLASM; PATHOLOGY; PERMEABILITY; PROCEDURES; TRENDS; TUMOR HYPOXIA; VASCULARIZATION;

ANTINEOPLASTIC AGENT; NANOMATERIAL; TUMOR MARKER;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DRUG DELIVERY SYSTEMS; EXTRACELLULAR MATRIX; HUMANS; NANOMEDICINE; NANOSTRUCTURES; NEOPLASMS; PERMEABILITY; TUMOR HYPOXIA; TUMOR MICROENVIRONMENT;

EID: 84997047916     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.11.015     Document Type: Review

References (107)

1. [1] Heldin, C.H., Rubin, K., Pietras, K., Ostman, A., High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 4:10 (2004), 806–813.
2. [2] Jain, R.K., Stylianopoulos, T., Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7:11 (2010), 653–664.
3. [3] Minchinton, A.I., Tannock, I.F., Drug penetration in solid tumours. Nat. Rev. Cancer 6:8 (2006), 583–592.
4. [4] Lammers, T., Kiessling, F., Hennink, W.E., Storm, G., Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J. Control. Release 161:2 (2012), 175–187.
5. [5] Malam, Y., Loizidou, M., Seifalian, A.M., Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 30:11 (2009), 592–599.
6. [6] Park, H.S., Kim, H.A., Jung, J.W., Kim, Y.K., Lee, S.K., Kim, S.S., Nahm, D.H., Metalloproteinase-9 is increased after toluene diisocyanate exposure in the induced sputum from patients with toluene diisocyanate-induced asthma. Clin. Exp. Allergy 33:1 (2003), 113–118.
7. [7] Hillaireau, H., Couvreur, P., Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 66:17 (2009), 2873–2896.
8. [8] Duncan, R., Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6:9 (2006), 688–701.
9. [9] Danhier, F., Feron, O., Préat, V., To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 148:2 (2010), 135–146.
10. [10] Matsumura, Y., Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46:12 Pt 1 (1986), 6387–6392.
11. [11] Fang, J., Nakamura, H., Maeda, H., The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63:3 (2011), 136–151.
12. [12] Maeda, H., Takeshita, J., Kanamaru, R., A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic. Int. J. Pept. Protein Res. 14:2 (1979), 81–87.
13. [13] Greish, K., Fang, J., Inutsuka, T., Nagamitsu, A., Maeda, H., Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin. Pharmacokinet. 42:13 (2003), 1089–1105.
14. [14] Davis, M.E., Chen, Z.G., Shin, D.M., Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7:9 (2008), 771–782.
15. [15] Danhier, F., Préat, V., Strategies to improve the EPR effect for the delivery of anti-cancer nanomedicines. Cancer Cell Microenviron., 2, 2015, e808.
16. [16] Petros, R.A., DeSimone, J.M., Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9:8 (2010), 615–627.
17. [17] Ragelle, H., Danhier, F., Préat, V., Langer, R., Anderson, D.G., Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures. Expert Opin. Drug Deliv., 2016.
18. [18] Allen, T.M., Chonn, A., Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 223:1 (1987), 42–46.
19. [19] Bangham, A.D., Standish, M.M., Watkins, J.C., Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13:1 (1965), 238–252.
20. [20] Langer, R., Folkman, J., Polymers for the sustained release of proteins and other macromolecules. Nature 263:5580 (1976), 797–800.
21. [21] Yatvin, M.B., Kreutz, W., Horwitz, B.A., Shinitzky, M., pH-sensitive liposomes: possible clinical implications. Science 210:4475 (1980), 1253–1255.
22. [22] Barenholz, Y., Doxil(R)–the first FDA-approved nano-drug: lessons learned. J. Control. Release 160:2 (2012), 117–134.
23. [23] Gordon, A.N., Fleagle, J.T., Guthrie, D., Parkin, D.E., Gore, M.E., Lacave, A.J., Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19:14 (2001), 3312–3322.
24. [24] Nichols, J.W., Bae, Y.H., EPR: evidence and fallacy. J. Control. Release 190 (2014), 451–464.
25. [25] Sparreboom, A., Scripture, C.D., Trieu, V., Williams, P.J., De, T., Yang, A., Beals, B., Figg, W.D., Hawkins, M., Desai, N., Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res. 11:11 (2005), 4136–4143.
26. [26] Henderson, I.C., Bhatia, V., Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert. Rev. Anticancer. Ther. 7:7 (2007), 919–943.
27. [27] Pirollo, K.F., Chang, E.H., Does a targeting ligand influence nanoparticle tumor localization or uptake?. Trends Biotechnol. 26:10 (2008), 552–558.
28. [28] Jain, R.K., Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46:1–3 (2001), 149–168.
29. [29] Verma, A., Uzun, O., Hu, Y., Hu, Y., Han, H.S., Watson, N., Chen, S., Irvine, D.J., Stellacci, F., Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat. Mater. 7:7 (2008), 588–595.
30. [30] Hrkach, J., Von, H.D., Mukkaram, A.M., Andrianova, E., Auer, J., Campbell, T., De, W.D., Figa, M., Figueiredo, M., Horhota, A., Low, S., McDonnell, K., Peeke, E., Retnarajan, B., Sabnis, A., Schnipper, E., Song, J.J., Song, Y.H., Summa, J., Tompsett, D., Troiano, G., Van Geen, H.T., Wright, J., LoRusso, P., Kantoff, P.W., Bander, N.H., Sweeney, C., Farokhzad, O.C., Langer, R., Zale, S., Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med., 4(128), 2012, 128ra39.
31. [31] Mamot, C., Ritschard, R., Wicki, A., Stehle, G., Dieterle, T., Bubendorf, L., Hilker, C., Deuster, S., Herrmann, R., Rochlitz, C., Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol. 13:12 (2012), 1234–1241.
32. [32] Stylianopoulos, T., Jain, R.K., Design considerations for nanotherapeutics in oncology. Nanomedicine 11:8 (2015), 1893–1907.
33. [33] Matsumura, Y., Gotoh, M., Muro, K., Yamada, Y., Shirao, K., Shimada, Y., Okuwa, M., Matsumoto, S., Miyata, Y., Ohkura, H., Chin, K., Baba, S., Yamao, T., Kannami, A., Takamatsu, Y., Ito, K., Takahashi, K., Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol. 15:3 (2004), 517–525.
34. [34] Zuckerman, J.E., Gritli, I., Tolcher, A., Heidel, J.D., Lim, D., Morgan, R., Chmielowski, B., Ribas, A., Davis, M.E., Yen, Y., Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc. Natl. Acad. Sci. U. S. A. 111:31 (2014), 11449–11454.
35. [35] Flynn, T., Wei, C., The pathway to commercialization for nanomedicine. Nanomedicine 1:1 (2005), 47–51.
36. [36] Nichols, J.W., Bae, Y.H., Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today 7:6 (2012), 606–618.
37. [37] Gillies, R.J., Schornack, P.A., Secomb, T.W., Raghunand, N., Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1:3 (1999), 197–207.
38. [38] Jain, R.K., Transport of molecules in the tumor interstitium: a review. Cancer Res. 47:12 (1987), 3039–3051.
39. [39] Nichols, A.W., Sports medicine and the Americans with Disabilities Act. Clin. J. Sport Med. 6:3 (1996), 190–195.
40. [40] Hare, J.I., Lammers, T., Ashford, M.B., Puri, S., Storm, G., Barry, S.T., Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv. Drug Deliv. Rev., 2016.
41. [41] Lammers, T., Peschke, P., Kuhnlein, R., Subr, V., Ulbrich, K., Debus, J., Huber, P., Hennink, W., Storm, G., Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. J. Control. Release 117:3 (2007), 333–341.
42. [42] Michiels, C., Tellier, C., Feron, O., Cycling hypoxia: a key feature of the tumor microenvironment. Biochim. Biophys. Acta 1866:1 (2016), 76–86.
43. [43] Maeda, H., Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 91 (2015), 3–6.
44. [44] Casazza, A., Di, C.G., Wenes, M., Finisguerra, V., Deschoemaeker, S., Mazzone, M., Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. Oncogene 33:14 (2014), 1743–1754.
45. [45] Miao, L., Huang, L., Exploring the tumor microenvironment with nanoparticles. Cancer Treat. Res. 166 (2015), 193–226.
46. [46] Kano, M.R., Bae, Y., Iwata, C., Morishita, Y., Yashiro, M., Oka, M., Fujii, T., Komuro, A., Kiyono, K., Kaminishi, M., Hirakawa, K., Ouchi, Y., Nishiyama, N., Kataoka, K., Miyazono, K., Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc. Natl. Acad. Sci. U. S. A. 104:9 (2007), 3460–3465.
47. [47] Kano, M.R., Komuta, Y., Iwata, C., Oka, M., Shirai, Y.T., Morishita, Y., Ouchi, Y., Kataoka, K., Miyazono, K., Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci. 100:1 (2009), 173–180.
48. [48] Glentis, A., Gurchenkov, V., Matic, V.D., Assembly, heterogeneity, and breaching of the basement membranes. Cell Adhes. Migr. 8:3 (2014), 236–245.
49. [49] Kalluri, R., Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 3:6 (2003), 422–433.
50. [50] Yokoi, K., Kojic, M., Milosevic, M., Tanei, T., Ferrari, M., Ziemys, A., Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment. Cancer Res. 74:16 (2014), 4239–4246.
51. [51] Sriraman, S.K., Aryasomayajula, B., Torchilin, V.P., Barriers to drug delivery in solid tumors. Tissue Barriers, 2, 2014, e29528.
52. [52] Khawar, I.A., Kim, J.H., Kuh, H.J., Improving drug delivery to solid tumors: priming the tumor microenvironment. J. Control. Release 201 (2015), 78–89.
53. [53] Egeblad, M., Nakasone, E.S., Werb, Z., Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell 18:6 (2010), 884–901.
54. [54] Krukiewicz, K., Zak, J.K., Biomaterial-based regional chemotherapy: local anticancer drug delivery to enhance chemotherapy and minimize its side-effects. Mater. Sci. Eng. C Mater. Biol. Appl. 62 (2016), 927–942.
55. [55] Norouzi, M., Nazari, B., Miller, D.W., Injectable hydrogel-based drug delivery systems for local cancer therapy. Drug Discov. Today, 2016.
56. [56] Karim, R., Palazzo, C., Evrard, B., Piel, G., Nanocarriers for the treatment of glioblastoma multiforme: current state-of-the-art. J. Control. Release 227 (2016), 23–37.
57. [57] Burgess, A., Shah, K., Hough, O., Hynynen, K., Focused ultrasound-mediated drug delivery through the blood-brain barrier. Expert. Rev. Neurother. 15:5 (2015), 477–491.
58. [58] Bastiancich, C., Vanvarenberg, K., Ucakar, B., Pitorre, M., Bastiat, G., Lagarce, F., Préat, V., Danhier, F., Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma. J. Control. Release 225 (2016), 283–293.
59. [59] Kiessling, F., Mertens, M.E., Grimm, J., Lammers, T., Nanoparticles for imaging: top or flop?. Radiology 273:1 (2014), 10–28.
60. [60] Schleich, N., Danhier, F., Préat, V., Iron oxide-loaded nanotheranostics: major obstacles to in vivo studies and clinical translation. J. Control. Release 198 (2015), 35–54.
61. [61] Ahmed, N., Fessi, H., Elaissari, A., Theranostic applications of nanoparticles in cancer. Drug Discov. Today 17:17–18 (2012), 928–934.
62. [62] Baetke, S.C., Lammers, T., Kiessling, F., Applications of nanoparticles for diagnosis and therapy of cancer. Br. J. Radiol., 88(1054), 2015, 20150207.
63. [63] Lammers, T., Rizzo, L.Y., Storm, G., Kiessling, F., Personalized nanomedicine. Clin. Cancer Res. 18:18 (2012), 4889–4894.
64. [64] Rizzo, L.Y., Theek, B., Storm, G., Kiessling, F., Lammers, T., Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr. Opin. Biotechnol. 24:6 (2013), 1159–1166.
65. [65] Alexiou, C., Arnold, W., Klein, R.J., Parak, F.G., Hulin, P., Bergemann, C., Erhardt, W., Wagenpfeil, S., Lubbe, A.S., Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 60:23 (2000), 6641–6648.
66. [66] Laurent, S., Saei, A.A., Behzadi, S., Panahifar, A., Mahmoudi, M., Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges. Expert Opin. Drug Deliv. 11:9 (2014), 1449–1470.
67. [67] Polyak, B., Fishbein, I., Chorny, M., Alferiev, I., Williams, D., Yellen, B., Friedman, G., Levy, R.J., High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc. Natl. Acad. Sci. U. S. A. 105:2 (2008), 698–703.
68. [68] Schleich, N., Po, C., Jacobs, D., Ucakar, B., Gallez, B., Danhier, F., Préat, V., Comparison of active, passive and magnetic targeting to tumors of multifunctional paclitaxel/SPIO-loaded nanoparticles for tumor imaging and therapy. J. Control. Release 194 (2014), 82–91.
69. [69] Koukourakis, M.I., Koukouraki, S., Giatromanolaki, A., Kakolyris, S., Georgoulias, V., Velidaki, A., Archimandritis, S., Karkavitsas, N.N., High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas–rationale for combination with radiotherapy. Acta Oncol. 39:2 (2000), 207–211.
70. [70] Chauhan, V.P., Popovic, Z., Chen, O., Cui, J., Fukumura, D., Bawendi, M.G., Jain, R.K., Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew. Chem. Int. Ed. Engl. 50:48 (2011), 11417–11420.
71. [71] Geng, Y., Dalhaimer, P., Cai, S., Tsai, R., Tewari, M., Minko, T., Discher, D.E., Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2:4 (2007), 249–255.
72. [72] Maeda, H., Wu, J., Okamoto, T., Maruo, K., Akaike, T., Kallikrein-kinin in infection and cancer. Immunopharmacology 43:2–3 (1999), 115–128.
73. [73] Maeda, H., Noguchi, Y., Sato, K., Akaike, T., Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res. 85:4 (1994), 331–334.
74. [74] Chambers, A.F., Matrisian, L.M., Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89:17 (1997), 1260–1270.
75. [75] Reichman, H.R., Farrell, C.L., Del Maestro, R.F., Effects of steroids and nonsteroid anti-inflammatory agents on vascular permeability in a rat glioma model. J. Neurosurg. 65:2 (1986), 233–237.
76. [76] Maeda, H., Wu, J., Sawa, T., Matsumura, Y., Hori, K., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65:1–2 (2000), 271–284.
77. [77] Danhier, F., Le Breton, A., Préat, V., RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol. Pharm. 9:11 (2012), 2961–2973.
78. [78] Nussenbaum, F., Herman, I.M., Tumor angiogenesis: insights and innovations. J. Oncol., 2010, 2010, 132641.
79. [79] Salgaller, M.L., Technology evaluation: bevacizumab, Genentech/Roche. Curr. Opin. Mol. Ther. 5:6 (2003), 657–667.
80. [80] Jain, R.K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:5706 (2005), 58–62.
81. [81] Danhier, F., Danhier, P., De Saedeleer, C.J., Fruytier, A.C., Schleich, N., des, R.A., Sonveaux, P., Gallez, B., Préat, V., Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors. Int. J. Pharm. 479:2 (2015), 399–407.
82. [82] Lee, C.G., Heijn, M., di, T.E., Griffon-Etienne, G., Ancukiewicz, M., Koike, C., Park, K.R., Ferrara, N., Jain, R.K., Suit, H.D., Boucher, Y., Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60:19 (2000), 5565–5570.
83. [83] Salnikov, A.V., Iversen, V.V., Koisti, M., Sundberg, C., Johansson, L., Stuhr, L.B., Sjoquist, M., Ahlstrom, H., Reed, R.K., Rubin, K., Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J. 17:12 (2003), 1756–1758.
84. [84] Bouzin, C., Feron, O., Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist. Updat. 10:3 (2007), 109–120.
85. [85] Yingling, J.M., Blanchard, K.L., Sawyer, J.S., Development of TGF-beta signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 3:12 (2004), 1011–1022.
86. [86] Griffon-Etienne, G., Boucher, Y., Brekken, C., Suit, H.D., Jain, R.K., Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res. 59:15 (1999), 3776–3782.
87. [87] Jang, S.H., Wientjes, M.G., Au, J.L., Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J. Pharmacol. Exp. Ther. 296:3 (2001), 1035–1042.
88. [88] Wang, J., Lu, Z., Gao, Y., Wientjes, M.G., Au, J.L., Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. Nanomedicine (London) 6:9 (2011), 1605–1620.
89. [89] Danhier, F., Danhier, P., Magotteaux, N., De, P.G., Ucakar, B., Karroum, O., Jordan, B., Gallez, B., Préat, V., Electron paramagnetic resonance highlights that the oxygen effect contributes to the radiosensitizing effect of paclitaxel. PLoS One, 7(7), 2012, e40772.
90. [90] Danhier, F., Magotteaux, N., Ucakar, B., Lecouturier, N., Brewster, M., Préat, V., Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel. Eur. J. Pharm. Biopharm. 73:2 (2009), 230–238.
91. [91] Taghian, A.G., Abi-Raad, R., Assaad, S.I., Casty, A., Ancukiewicz, M., Yeh, E., Molokhia, P., Attia, K., Sullivan, T., Kuter, I., Boucher, Y., Powell, S.N., Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J. Clin. Oncol. 23:9 (2005), 1951–1961.
92. [92] Ansiaux, R., Baudelet, C., Jordan, B.F., Beghein, N., Sonveaux, P., De, W.J., Martinive, P., Gregoire, V., Feron, O., Gallez, B., Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin. Cancer Res. 11:2 Pt 1 (2005), 743–750.
93. [93] Segers, J., F. Di, V., Ansiaux, R., Martinive, P., Feron, O., Wallemacq, P., Gallez, B., Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the ‘normalization’ window of the tumor vasculature. Cancer Lett. 244:1 (2006), 129–135.
94. [94] Tong, R.T., Boucher, Y., Kozin, S.V., Winkler, F., Hicklin, D.J., Jain, R.K., Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64:11 (2004), 3731–3736.
95. [95] Pluen, A., Boucher, Y., Ramanujan, S., McKee, T.D., Gohongi, T., di T., E., Brown, E.B., Izumi, Y., Campbell, R.B., Berk, D.A., Jain, R.K., Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc. Natl. Acad. Sci. U. S. A. 98:8 (2001), 4628–4633.
96. [96] Kuriyama, N., Kuriyama, H., Julin, C.M., Lamborn, K.R., Israel, M.A., Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model. Cancer Res. 61:5 (2001), 1805–1809.
97. [97] Alexandrakis, G., Brown, E.B., Tong, R.T., McKee, T.D., Campbell, R.B., Boucher, Y., Jain, R.K., Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors. Nat. Med. 10:2 (2004), 203–207.
98. [98] Goodman, T.T., Olive, P.L., Pun, S.H., Increased nanoparticle penetration in collagenase-treated multicellular spheroids. Int. J. Nanomedicine 2:2 (2007), 265–274.
99. [99] Eikenes, L., Tari, M., Tufto, I., Bruland, O.S., de Lange, D.C., Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br. J. Cancer 93:1 (2005), 81–88.
100. [100] Masterson, R., Hewitson, T.D., Kelynack, K., Martic, M., Parry, L., Bathgate, R., Darby, I., Becker, G., Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro. Nephrol. Dial. Transplant. 19:3 (2004), 544–552.
101. [101] Stylianopoulos, T., Wong, C., Bawendi, M.G., Jain, R.K., Fukumura, D., Multistage nanoparticles for improved delivery into tumor tissue. Methods Enzymol. 508 (2012), 109–130.
102. [102] Zhu, L., Kate, P., Torchilin, V.P., Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano 6:4 (2012), 3491–3498.
103. [103] Sugahara, K.N., Teesalu, T., Karmali, P.P., Kotamraju, V.R., Agemy, L., Girard, O.M., Hanahan, D., Mattrey, R.F., Ruoslahti, E., Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16:6 (2009), 510–520.
104. [104] Sugahara, K.N., Teesalu, T., Karmali, P.P., Kotamraju, V.R., Agemy, L., Greenwald, D.R., Ruoslahti, E., Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328:5981 (2010), 1031–1035.
105. [105] Tong, R., Langer, R., Nanomedicines targeting the tumor microenvironment. Cancer J. 21:4 (2015), 314–321.
106. [106] Liu, D., Yang, F., Xiong, F., Gu, N., The smart drug delivery system and its clinical potential. Theranostics 6:9 (2016), 1306–1323.
107. [107] Mura, S., Nicolas, J., Couvreur, P., Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 12:11 (2013), 991–1003.